Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$4.70 0.04 (0.86%)
2/9/2010 4:00 PM

Idera Pharmaceuticals, Inc. (IDRA)

CAPS Rating:
***

The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating IDRA

Add Stock to Watchlist

What the Community Thinks

Total Members

53 Outperforms
12 Underperforms
 

All-Stars

10 Outperforms
5 Underperforms
 

Wall Street

3 Outperforms
0 Underperforms
 

Members bullish on IDRA are also bullish on:

Members bearish on IDRA are also bearish on:

Ticker Tags

Growth (1902), Biotechnology (220), Micro Cap (4701), Aggressive Growth (860), Defensive (1457), Healthcare (711)
Suggest a tag

Idera Pharmaceuticals, Inc. At A Glance

Current Price: $4.70
Last Trade Time: 2/9/2010 4:00 PM
Open: $4.74
Previous Close: $4.66
Daily Range: $4.64 - $4.77
52-Week Range: $4.48 - $8.50
Volume: 20,332
Market Cap: $110.31M
P/E Ratio: 27.41
Compare Our Special Broker Offers!

Stock Trends

IDRA VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Idera Pharmaceuticals, Inc. (IDRA)

Avatar lemapud (< 20) Submitted: 1/22/07 5:20 PM

IDERA has cutting edge new science in the field of immunology. They have had their share of followers and detractors over the years, and survived through it all. They have a strong company plan now, good partners, and exciting therapies that will be used to combat aids, cancer, and other human malad...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

3

Idera Pharmaceuticals, Inc. (IDRA)

Avatar zzlangerhans (99.64) Submitted: 3/18/09 12:26 PM

In October the lead compound IMO2055 failed a phase II trial for renal cell carcinoma. What kept the stock from tanking more than 25% on the bad news, considering that the whole pipeline consists of related TLR9 agonists and antagonists? Probably the significant number of collaborations with big pha...More

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 11 :   1 2 3 Next »

Recs

0

 (IDRA)

Avatar zzlangerhans (99.64) Submitted: 11/18/09 9:58 AM : Outperform Start Price: $5.12 IDRA Score: -4.93

Rather than an endorsement of Idera's pipeline, this green thumb represents confidence in their low burn and the volatility of the stock. Having stabilized off a recent spike and plunge (for no discernible reason), Idera is primed to reascend and has all the time in the world to get there.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (IDRA)

Avatar ScreenerStizBear (< 20) Submitted: 6/26/08 2:26 PM : Underperform Start Price: $14.63 IDRA Score: 53.63

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (IDRA)

Avatar goldnrtrvrlvr (< 20) Submitted: 5/05/08 7:24 AM : Outperform Start Price: $14.75 IDRA Score: -46.97

New Hi

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (IDRA)

Avatar fouadtawfig (< 20) Submitted: 4/16/08 11:27 AM : Outperform Start Price: $13.03 IDRA Score: -46.17

exiting patents needed for farmuecitical market will reflect son expanded orders and deman for larger supply.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (IDRA)

Avatar mbeleza (< 20) Submitted: 11/14/07 5:56 AM : Underperform Start Price: $12.15 IDRA Score: 36.60

It´s at it's most

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 11 :   1 2 3 Next »

Wall Street

Results 1 - 3 of 3  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackNobleFinanc 88.28 11/21/08 Outperform NS $5.98-21.40%+44.32%-65.72
TrackMDB < 20 05/22/07 Outperform NS $8.74-46.22%-25.74%-20.49
TrackMerriman < 20 02/07/07 Outperform NS $9.45-50.26%-21.58%-28.68

Results 1 - 3 of 3  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD01 828ms